Use of ketamine for treatment resistant depression
Updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada
Bibliographic Data
| ID | 15517826 |
|---|---|
| Authors | Carson Chrenek (University of Alberta, corresponding author), Bryan Duong (University of Alberta Hospital), Atul Khullar (Grey Nuns Community Hospital), Chris McRee (Grey Nuns Community Hospital), Rejish K Thomas (0000-0002-7082-4457, Grey Nuns Community Hospital), Rejish Thomas, Jennifer Swainson (0000-0002-6071-1395, University of Alberta, corresponding author) |
| Year | 2024 |
| Volume | 14 |
| Pages | 1283733-1283733 |
| Publication date | 2024-01-08 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2023.1283733 |
| PMID | 38260793 |
| OpenAlex | W4390664715 |
| Language | EN |
| References cited | 90 |
Evidence for the use of ketamine in resistant depression has grown in recent years, with evolving data to support and direct its clinical use. There is an increasing body of evidence to guide judicious use of ketamine in various clinical circumstances, for a population of patients with a high burden of suffering and morbidity. While large-scale, randomized controlled trials, comparative studies, and longer-term treatment outcomes is lacking, this community case study illustrates that currently available evidence can be applied to real-world clinical settings with complex patients. As cost is often a significant barrier to accessing initial and/or maintenance IV or esketamine treatments, public ketamine programs may incorporate SL or IN ketamine to support a sustainable and accessible treatment model. Three of such models are described
Adverse effect · Depression (economics · Dosing · Intensive care medicine · Ketamine · Major depressive disorder · Mood · Psychiatry · Tolerability · Treatment-resistant depression · Bipolar Disorder and Treatment · Medicine · Treatment of Major Depression · Tryptophan and brain disorders · Pharmacology
Development of a rational scale to assess the harm of drugs of potential misuse
Canadian Network for Mood and Anxiety Treatments ( Canmat ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder
A Retrospective Naturalistic Study Comparing the Efficacy of Ketamine and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression
The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication
Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety
A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression
Intravenous ketamine for depression
| Citation velocity | historical |
|---|---|
| Highly cited | No |